Title
Category
Credits
Event date
Cost
CAR T-Cell Therapies in Hematologic Malignancies: Challenges and Strategies
  • Acute Lymphoblastic Leukemia
  • Hematologic Malignancies
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Multiple CAR T-cell therapies are approved for the treatment of certain relapsed or refractory hematologic malignancies with promising clinical outcomes. However, treatment with CAR T-cell therapy is not without risk and can result in severe and potentially fatal toxicities. Although these toxicities are generally reversible, early recognition and implementation of an appropriate management strategy are essential.
Optimizing the Use of Bispecific Antibodies in Hematologic Malignancies
  • Acute Lymphoblastic Leukemia
  • Hematologic Malignancies
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Immunotherapy using antibody drug conjugates, immune check point inhibitors, and chimeric antigen receptor (CAR) T-cells has significantly transformed the treatment landscape of relapsed or refractory hematologic malignancies. Bispecific antibodies represent a novel immunotherapy approach with remarkable efficacy for the treatment of relapsed/refractory hematologic malignancies. However, they also have a distinct toxicity profile associated with T-cell activation.
Managing Earlier Integration of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia
  • Acute Lymphoblastic Leukemia
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
While blinatumomab has been utilized in the setting of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) for years, emerging data has shown promising clinical efficacy with its use as post-remission therapy. Knowledge of key trial findings regarding blinatumomab consolidation for both Philadelphia chromosome-positive and Philadelphia chromosome-negative B-ALL may allow providers to choose up-front regimens with the ability to improve rates of molecular response and overall survival.
Managing Post-Treatment Complications for Multiple Myeloma and Acute Lymphocytic Leukemia
  • Acute Lymphoblastic Leukemia
  • Multiple Myeloma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
As additional, more effective, and novel therapies are added to the repertoire of cancer therapy, there are increasing numbers of cancer survivors, and these survivors are living for longer periods of time from diagnosis. In the case of those diagnosed with multiple myeloma (MM), due to the growing number of treatment options and improved supportive care, patients are living longer, and MM is becoming more of chronic disease.